A Multivalent Kaposi Sarcoma-associated Herpesvirus-like Particle Vaccine Capable of Eliciting High Titers of Neutralizing Antibodies in Immunized Rabbits

Overview

Journal Vaccine

Specialty Allergy & Immunology

Date 2019 Jun 16

PMID 31201053

Citations 14

Authors

David H Mulama

Lorraine Z Mutsvunguma

Jennifer Totonchy

Peng Ye

Joslyn Foley

Gabriela M Escalante

Esther Rodriguez

Ramina Nabiee

Murali Muniraju

Felix Wussow

Anne K Barasa

Javier Gordon Ogembo

Affiliations

Soon will be listed here.

Abstract

Kaposi sarcoma-associated herpesvirus (KSHV) is an emerging pathogen and the causative agent of multiple cancers in immunocompromised patients. To date, there is no licensed prophylactic KSHV vaccine. In this study, we generated a novel subunit vaccine that incorporates four key KSHV envelope glycoproteins required for viral entry in diverse cell types (gpK8.1, gB, and gH/gL) into a single multivalent KSHV-like particle (KSHV-LP). Purified KSHV-LPs were similar in size, shape, and morphology to KSHV virions. Vaccination of rabbits with adjuvanted KSHV-LPs generated strong glycoprotein-specific antibody responses, and purified immunoglobulins from KSHV-LP-immunized rabbits neutralized KSHV infection in epithelial, endothelial, fibroblast, and B cell lines (60-90% at the highest concentration tested). These findings suggest that KSHV-LPs may be an ideal platform for developing a safe and effective prophylactic KSHV vaccine. We envision performing future studies in animal models that are susceptible to KSHV infection, to determine correlates of immune protection in vivo.

Citing Articles

Prokaryote- and Eukaryote-Based Expression Systems: Advances in Post-Pandemic Viral Antigen Production for Vaccines.

Khudainazarova N, Granovskiy D, Kondakova O, Ryabchevskaya E, Kovalenko A, Evtushenko E Int J Mol Sci. 2024; 25(22).

PMID: 39596049 PMC: 11594041. DOI: 10.3390/ijms252211979.

Bladder Adenocarcinoma in a Constellation of Multiple Site Malignancies: An Unusual Case and Systematic Review.

Porav-Hodade D, Gherasim R, Loghin A, Lazar B, Cotoi O, Badea M Diagnostics (Basel). 2024; 14(22).

PMID: 39594177 PMC: 11592427. DOI: 10.3390/diagnostics14222510.

Development of KSHV vaccine platforms and chimeric MHV68-K-K8.1 glycoprotein for evaluating the immunogenicity and efficacy of KSHV vaccine candidates.

Yang W, Kim D, Kang S, Lai C, Cha I, Chang P mBio. 2024; 15(12):e0291324.

PMID: 39475238 PMC: 11633179. DOI: 10.1128/mbio.02913-24.

Hypoxic reactivation of Kaposi's sarcoma associated herpesvirus.

Singh R, Torne A, Robertson E Cell Insight. 2024; 3(6):100200.

PMID: 39391006 PMC: 11466537. DOI: 10.1016/j.cellin.2024.100200.

A retrospective study of Kaposi's sarcoma in Hotan region of Xinjiang, China.

Yang H, He F, Jielili A, Zhang Z, Cui Z, Wang J Medicine (Baltimore). 2023; 102(41):e35552.

PMID: 37832074 PMC: 10578766. DOI: 10.1097/MD.0000000000035552.

References

Wu T, Qian J, Ang J, Sun R . Vaccine prospect of Kaposi sarcoma-associated herpesvirus. Curr Opin Virol. 2012; 2(4):482-8. DOI: 10.1016/j.coviro.2012.06.005. View

Zhu L, Puri V, Chandran B . Characterization of human herpesvirus-8 K8.1A/B glycoproteins by monoclonal antibodies. Virology. 1999; 262(1):237-49. DOI: 10.1006/viro.1999.9900. View

Labo N, Miley W, Marshall V, Gillette W, Esposito D, Bess M . Heterogeneity and breadth of host antibody response to KSHV infection demonstrated by systematic analysis of the KSHV proteome. PLoS Pathog. 2014; 10(3):e1004046. PMC: 3968157. DOI: 10.1371/journal.ppat.1004046. View

Kim J, Lee S, Li L, Park H, Park J, Lee K . High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice. PLoS One. 2011; 6(4):e18556. PMC: 3084703. DOI: 10.1371/journal.pone.0018556. View

Sok D, Le K, Vadnais M, Saye-Francisco K, Jardine J, Torres J . Rapid elicitation of broadly neutralizing antibodies to HIV by immunization in cows. Nature. 2017; 548(7665):108-111. PMC: 5812458. DOI: 10.1038/nature23301. View

Hahn A, Kaufmann J, Wies E, Naschberger E, Panteleev-Ivlev J, Schmidt K . The ephrin receptor tyrosine kinase A2 is a cellular receptor for Kaposi's sarcoma–associated herpesvirus. Nat Med. 2012; 18(6):961-6. PMC: 3645317. DOI: 10.1038/nm.2805. View

Pantua H, McGinnes L, Peeples M, Morrison T . Requirements for the assembly and release of Newcastle disease virus-like particles. J Virol. 2006; 80(22):11062-73. PMC: 1642154. DOI: 10.1128/JVI.00726-06. View

Hahn A, Birkmann A, Wies E, Dorer D, Mahr K, Sturzl M . Kaposi's sarcoma-associated herpesvirus gH/gL: glycoprotein export and interaction with cellular receptors. J Virol. 2008; 83(1):396-407. PMC: 2612313. DOI: 10.1128/JVI.01170-08. View

Soulier J, GROLLET L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P . Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood. 1995; 86(4):1276-80. View

10.

Boigard H, Alimova A, Martin G, Katz A, Gottlieb P, Galarza J . Zika virus-like particle (VLP) based vaccine. PLoS Negl Trop Dis. 2017; 11(5):e0005608. PMC: 5436897. DOI: 10.1371/journal.pntd.0005608. View

11.

Hesse F, Wagner R . Developments and improvements in the manufacturing of human therapeutics with mammalian cell cultures. Trends Biotechnol. 2000; 18(4):173-80. DOI: 10.1016/s0167-7799(99)01420-1. View

12.

Kundi M . New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines. 2007; 6(2):133-40. DOI: 10.1586/14760584.6.2.133. View

13.

Chiuppesi F, Nguyen J, Park S, Contreras H, Kha M, Meng Z . Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice. J Virol. 2018; 92(19). PMC: 6146800. DOI: 10.1128/JVI.01012-18. View

14.

Cheru L, Wu Y, Diouf A, Moretz S, Muratova O, Song G . The IC(50) of anti-Pfs25 antibody in membrane-feeding assay varies among species. Vaccine. 2010; 28(27):4423-9. PMC: 2880321. DOI: 10.1016/j.vaccine.2010.04.036. View

15.

McHugh D, Caduff N, Barros M, Ramer P, Raykova A, Murer A . Persistent KSHV Infection Increases EBV-Associated Tumor Formation In Vivo via Enhanced EBV Lytic Gene Expression. Cell Host Microbe. 2017; 22(1):61-73.e7. DOI: 10.1016/j.chom.2017.06.009. View

16.

Cheeseman H, Olejniczak N, Rogers P, Evans A, King D, Ziprin P . Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies. J Virol. 2016; 91(1). PMC: 5165208. DOI: 10.1128/JVI.01762-16. View

17.

Metz S, Gardner J, Geertsema C, Le T, Goh L, Vlak J . Effective chikungunya virus-like particle vaccine produced in insect cells. PLoS Negl Trop Dis. 2013; 7(3):e2124. PMC: 3597470. DOI: 10.1371/journal.pntd.0002124. View

18.

Myoung J, Ganem D . Generation of a doxycycline-inducible KSHV producer cell line of endothelial origin: maintenance of tight latency with efficient reactivation upon induction. J Virol Methods. 2011; 174(1-2):12-21. PMC: 3095772. DOI: 10.1016/j.jviromet.2011.03.012. View

19.

Lu Y, Welsh J, Swartz J . Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines. Proc Natl Acad Sci U S A. 2013; 111(1):125-30. PMC: 3890838. DOI: 10.1073/pnas.1308701110. View

20.

Walsh G . Biopharmaceutical benchmarks 2006. Nat Biotechnol. 2006; 24(7):769-76. DOI: 10.1038/nbt0706-769. View